Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | AOC1 | P19801 | 2/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16149771 | 0.85 | TAAR1 (0.43) | PNMTDPP4 | |
| SCHEMBL7395144 | 0.80 | GABRA1 (0.39) | — | |
| SCHEMBL4064007 | 0.76 | — | — | |
| SCHEMBL1385609 | 0.74 | — | — | |
| SCHEMBL21571282 | 0.74 | — | — | |
| SCHEMBL18705643 | 0.74 | — | — | |
| SCHEMBL5851796 | 0.74 | — | — | |
| SCHEMBL2072871 | 0.74 | — | — | |
| SCHEMBL4650365 | 0.73 | TAAR1 (0.34) | PNMTDPP4 | |
| SCHEMBL9683627 | 0.73 | TAAR1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 841 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | ARIVA MED GMBH (AT) | 2023-06-08 | — | — | US | claimed |
| EP-4135683-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GMBH (AT) | 2023-02-22 | — | — | EP | claimed |
| WO-2021209596-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-10-21 | — | — | WO | claimed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | claimed |
| CN-110337436-A | Substituted 1,2,4- thiadiazolyl group pyrrolones and 1,2,4- thiadiazolyl group hydantoins and its salt and its purposes as herbicide | 拜耳作物科学股份公司 | 2019-10-15 | — | — | CN | claimed |
| CN-105408314-B | Process for preparing 3, 5-bis (fluoroalkyl) pyrazole derivatives from α -dihaloamines | 拜耳作物科学股份公司 | 2018-04-24 | — | — | CN | claimed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | claimed |
| EP-3096751-A1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics AG (AT) | 2016-11-30 | — | — | EP | claimed |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2016-11-17 | — | — | US | claimed |
| WO-2015110481-A1 | 12-EPI-PLEUROMUTILINS | NABRIVA THERAPEUTICS AG (AT) | 2015-07-30 | — | — | WO | claimed |
| EP-1140856-B1 | FLUORESCENT DYES FOR SOLID PHASE AND SOLUTION PHASE SCREENING | NOVARTIS AG (CH) | 2005-04-27 | — | — | EP | claimed |
| EP-4397366-A2 | GLYCYRRHETINIC ACID DERIVATIVES FOR TREATING HYPERKALEMIA | Ardelyx, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240208989-A1 | NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF | ARIVA MED GMBH (AT) | 2024-06-27 | — | — | US | disclosed |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | ARDELYX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-4459405-A | Desacetylcephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-07-10 | — | — | US | disclosed |
| EP-0109816-A1 | N-substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process | ELI LILLY AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
| EP-0109817-A2 | Process for preparing oxazolinoazetidinones | ELI LILLY AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
| EP-0109300-A2 | Desacetylcephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-05-23 | — | — | EP | disclosed |
| US-4436596-A | N-Substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process | ELI LILLY AND COMPANY (US) | 1984-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208989-A1 | NOVEL 12-EPI-MUTILIN COMPOUNDS AND USES THEREOF | MTNR1A, MSH6, MSH2 | PNMT 2558/4885DPP4 1065/4885AOC1 3385/4885 |
| US-20240209019-A1 | COMPOUNDS AND METHODS FOR TREATING HYPERKALEMIA | REN, NHERF1, KCNJ11 | PNMT 4593/4885DPP4 882/4885AOC1 2379/4885 |
| US-20160332963-A1 | 12-EPI PLEUROMUTILINS | MLN, TCF12, PLEC | PNMT 1745/4885DPP4 2444/4885AOC1 3723/4885 |
| US-20230174509-A1 | THERAPEUTIC USE OF PLEUROMUTILINS | MLN, PLEC, PELP1 | PNMT 1141/4885DPP4 339/4885AOC1 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.